NRAS and melanoma: Therefore, the aim of the present study was to test the applicability of this combination in vivo using three xenograft models as well as to bolster the concept that BRAF inhibitors enhanced the antitumor efficacy of MEK inhibitors in NRAS-mutated melanoma.